SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company dedicated to developing innovative therapies for a broad range of cancer indications. Their focus is on novel therapeutics, including galinpepimut-S, a WT1-targeting immunotherapeutic, and SLS009, a highly selective CDK9 inhibitor. The company collaborates with leading institutions like Memorial Sloan Kettering Cancer Center and GenFleet Therapeutics, and is committed to advancing cancer treatment through clinical trials and scientific research.
Industries
Nr. of Employees
small (1-50)
SELLAS Life Sciences Group, Inc.
Hamilton, Hamilton, Bermuda, North America
Products
Galinpepimut-S (multi-peptide WT1-targeting vaccine)
A multi-peptide cancer immunotherapeutic designed to target WT1-expressing tumors by eliciting CD4+ and CD8+ T-cell responses; includes heteroclitic peptide modifications intended to enhance immunogenicity.
SLS009 (selective CDK9 inhibitor)
A next-generation small-molecule inhibitor selective for CDK9 developed to reduce expression of proteins such as MCL1 and c-MYC, with the aim of inducing cancer cell apoptosis and enabling combination use with other agents.
Galinpepimut-S (multi-peptide WT1-targeting vaccine)
A multi-peptide cancer immunotherapeutic designed to target WT1-expressing tumors by eliciting CD4+ and CD8+ T-cell responses; includes heteroclitic peptide modifications intended to enhance immunogenicity.
SLS009 (selective CDK9 inhibitor)
A next-generation small-molecule inhibitor selective for CDK9 developed to reduce expression of proteins such as MCL1 and c-MYC, with the aim of inducing cancer cell apoptosis and enabling combination use with other agents.
Services
Expanded access program evaluation and coordination
Evaluation of individual expanded access requests for investigational therapies, with physician-submitted request handling and eligibility assessment.
Partnering and licensing support
Management of licensing agreements and external collaborations for development and commercialization rights across territories.
Clinical trial conduct and coordination
Operational coordination of multi-center clinical trials including protocol implementation, endpoint collection, and global site enrollment.
Expanded access program evaluation and coordination
Evaluation of individual expanded access requests for investigational therapies, with physician-submitted request handling and eligibility assessment.
Partnering and licensing support
Management of licensing agreements and external collaborations for development and commercialization rights across territories.
Clinical trial conduct and coordination
Operational coordination of multi-center clinical trials including protocol implementation, endpoint collection, and global site enrollment.
Expertise Areas
- Clinical trial management
- Immuno-oncology vaccine development
- Small-molecule oncology drug development
- Biomarker-driven clinical development
Key Technologies
- Peptide-based immunotherapy
- AI-driven peptide epitope design
- Selective CDK9 small-molecule inhibitors
- Intracellular cytokine flow cytometry